GS ORI-GO
Live / Applied — Non-final action written — not yet mailed (as of 05 Oct 2026)
Now
Refused for now — an office action was mailed 05 Oct 2026.
A response is due by 05 Apr 2027; with no response the application is abandoned.
What this means for you
Not registered yet, but its 18 Jun 2026 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79457737
- Mark type
- Word mark
- Filed
- 18 Jun 2026
Goods and services
- Class 001 — Chemicals: Cells for scientific, laboratory, medical research and clinical use including genetic material for protein production; biological preparations, not for medical use, namely, genetically modified cells and vectors for production of human, animal and synthetic proteins, for clinical and commercial use in scientific research, and for use in pharmaceutical research; kits consisting of cell lines, reagents, enzyme substrates and/or genetically modified chemical preparations; reagents, nucleic acids and nucleotides for scientific use and for research purposes in the field of clinical research, drug development, research in agriculture and genetics; reagent kits consisting of reagents and chemical preparations; samples of nucleotide sequence variants and modifications for use in the field of scientific research, clinical research and scientific research in diagnosis.
- Class 005 — Pharmaceuticals: Biological preparations, for medical use, namely, genetically modified cells and genetically modified vectors for production of human, animal and synthetic proteins for medical purposes and, for clinical and commercial use in human and animal therapies; Gene therapy products, namely, modified cells and modified cell platforms.
- Class 042 — Scientific and technological services: Scientific and medical research in the field of biotechnology; Technical consultancy and project planning in the field of biological research relating to proteins; research and development in the field of proteins for others; scientific research and laboratory services in the fields of editing, modification, engineering and regulation of genes, genome and cells for the development of pharmaceutical and biological preparations for human and veterinary use; aggregating, analyzing and providing data in the field of genomics; custom design and development of cell lines designed for others for scientific research, drug discovery and development; scientific research and laboratory services in the fields of editing, modification, engineering and regulation of genes, genome and cells for the development of medical diagnostic products.
Owner
- Lonza Ltd., CH
Prosecution history
- 06 Oct 2026 — NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
- 05 Oct 2026 — NON-FINAL ACTION WRITTEN
- 28 Sept 2026 — ASSIGNED TO EXAMINER
- 10 Sept 2026 — APPLICATION FILING RECEIPT MAILED
- 10 Sept 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 10 Sept 2026 — SN ASSIGNED FOR SECT 66A APPL FROM IB